STOCK TITAN
  1. Home
  2. News
  3. HROW

Harrow Health Inc - HROW STOCK NEWS

Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.

Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.

Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.

Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.

Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.

News

Harrow Announces New Appointments to its Board of Directors

Rhea-AI Summary
Harrow (Nasdaq: HROW) has appointed Adrienne Graves, Ph.D., and Lauren Silvernail to its Board of Directors, bringing the total number of members to six. The company aims to leverage their expertise to execute its Strategic Plan and maximize stockholder value by leveraging its dynamic product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
management
-
News

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Rhea-AI Summary
Harrow (Nasdaq: HROW) launches VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED) in the U.S. VEVYE offers rapid onset with clinically and statistically meaningful improvement beginning as early as 15 days, with sustained improvement over 56 weeks. VEVYE patients have access to a 100% money-back guarantee program. The drug is powered by a unique combination of cyclosporine and a water-free semifluorinated alkane delivery vehicle, solving an unmet need for eyecare professionals treating the tens of millions of American chronic dry eye disease sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News

Melt Pharmaceuticals Provides Corporate Update

Rhea-AI Summary
Melt Pharmaceuticals, Inc. (Melt) provided a corporate update, announcing the success of MELT-300 in its Phase 2 Pivotal Efficacy and Safety Study for procedural sedation in cataract surgery. The non-IV, non-opioid tablet, using Catalent Inc.'s fast-dissolving Zydis® delivery technology, is expected to begin Phase 3 program activities in the first quarter of 2024. Additionally, Melt settled its debt with its largest shareholder, Harrow, Inc. (Nasdaq: HROW), and secured funding for the Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
News

Harrow Partners with Leading Healthcare Market Access Technology Platforms

Rhea-AI Summary
Harrow (Nasdaq: HROW) has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED). The partnerships with PhilRx, Apollo Care, and PARx Solutions aim to simplify the prior authorization process, establish copay program deployment, and help prescribers overcome challenges. Harrow's commitment to patient access and innovative, affordable ophthalmic pharmaceutical products is reflected in its market access program for VEVYE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
partnership
-
News

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Rhea-AI Summary
Harrow (Nasdaq: HROW) has completed the transfer of the New Drug Application (NDA) for TRIESENCE, a synthetic corticosteroid used for various eye conditions, ahead of the previously agreed date. The company has also acquired the U.S. commercial rights to TRIESENCE and is making progress in manufacturing commercial batches. Harrow is implementing market access, marketing, inventory management, and brand-leveraging strategies to re-launch TRIESENCE in the U.S., showing a promising outlook for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News

Harrow to Present at Two Investor Conferences in November

Rhea-AI Summary
Harrow (Nasdaq: HROW) Announces Participation in Upcoming Conferences, BTIG 3rd Annual Ophthalmology Day and Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
News

Harrow Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
Harrow (Nasdaq: HROW) - Harrow, a leading U.S. eyecare pharmaceutical company, reported record revenues of $34.3 million in the third quarter of 2023, marking a 50% increase over the prior-year revenues. The company also announced a GAAP net loss of $(4.4 million) and an adjusted EBITDA of $9.2 million, representing a 270% increase over the prior-year quarter. Additionally, Harrow completed the transfer of NDAs and launched several products in the U.S., including FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE®. CEO Mark L. Baum commented on the results, highlighting the exceptional performance of the IHEEZO® launch and the substantial increase in unit demand in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.01%
Tags
earnings
-
News

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

Rhea-AI Summary
Harrow, a leading U.S. eyecare pharmaceutical company, will release its financial results for Q3 2023 on November 13, 2023. The company will also provide a business update during a conference call and live webcast at 4:45 p.m. Eastern Time. Participants can access the webcast on harrow.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
earnings
-
News

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Rhea-AI Summary
Harrow has completed the transfer of New Drug Applications for several eyecare pharmaceutical products and has launched them in the U.S. market. The company aims to increase brand awareness and sales through its marketing and sales teams. Product orders can be made through Cardinal's Cordlogistics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
News

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

Rhea-AI Summary
Harrow (Nasdaq: HROW) changes its corporate name to Harrow, Inc. to align with its strategic focus on eyecare pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Stock HROW logo
Harrow Health Inc

Nasdaq:HROW

HROW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HROW Stock Data

855.34M
30.01M
13.49%
59.11%
7.72%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE